Role of Abl in airway hyperresponsiveness and airway remodeling

BackgroundAsthma is a chronic disease that is characterized by airway hyperresponsiveness and airway remodeling. The underlying mechanisms that mediate the pathological processes are not fully understood. Abl is a non-receptor protein tyrosine kinase that has a role in the regulation of smooth muscle contraction and smooth muscle cell proliferation in vitro. The role of Abl in airway hyperresponsiveness and airway remodeling in vivo is largely unknown.MethodsTo evaluate the role of Abl in asthma pathology, we assessed the expression of Abl in airway tissues from the ovalbumin sensitized and challenged mouse model, and human asthmatic airway smooth muscle cells. In addition, we generated conditional knockout mice in which Abl expression in smooth muscle was disrupted, and then evaluated the effects of Abl conditional knockout on airway resistance, smooth muscle mass, cell proliferation, IL-13 and CCL2 in the mouse model of asthma. Furthermore, we determined the effects of the Abl pharmacological inhibitors imatinib and GNF-5 on these processes in the animal model of asthma.ResultsThe expression of Abl was upregulated in airway tissues of the animal model of asthma and in airway smooth muscle cells of patients with severe asthma. Conditional knockout of Abl attenuated airway resistance, smooth muscle mass and staining of proliferating cell nuclear antigen in the airway of mice sensitized and challenged with ovalbumin. Interestingly, conditional knockout of Abl did not affect the levels of IL-13 and CCL2 in bronchoalveolar lavage fluid of animals treated with ovalbumin. However, treatment with imatinib and GNF-5 inhibited the ovalbumin-induced increase in IL-13 and CCL2 as well as airway resistance and smooth muscle growth in animals.ConclusionsThese results suggest that the altered expression of Abl in airway smooth muscle may play a critical role in the development of airway hyperresponsiveness and airway remodeling in asthma. Our findings support the concept that Abl may be a novel target for the development of new therapy to treat asthma.

[1]  D. Tang,et al.  Physiologic Properties and Regulation of the Actin Cytoskeleton in Vascular Smooth Muscle , 2008, Journal of cardiovascular pharmacology and therapeutics.

[2]  H. Kita,et al.  CD38-deficient mice have reduced airway hyperresponsiveness following IL-13 challenge. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[3]  S. Lira,et al.  The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity. , 2007, American journal of respiratory and critical care medicine.

[4]  A. Ammit,et al.  Airway smooth muscle cell hyperplasia: a therapeutic target in airway remodeling in asthma? , 2003, Progress in cell cycle research.

[5]  E. Olson,et al.  SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. , 1996, Circulation research.

[6]  D. Tang,et al.  Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[7]  H. Kita,et al.  Role of CD38 in TNF-α-induced airway hyperresponsiveness , 2008 .

[8]  J. Benovic,et al.  MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[9]  D. Tang,et al.  Raf-1, actin dynamics, and abelson tyrosine kinase in human airway smooth muscle cells. , 2013, American journal of respiratory cell and molecular biology.

[10]  A. Baruzzi,et al.  The tyrosine kinase Abl is a component of macrophage podosomes and is required for podosome formation and function , 2012, European journal of immunology.

[11]  D. Tang,et al.  Abl activation regulates the dissociation of CAS from cytoskeletal vimentin by modulating CAS phosphorylation in smooth muscle. , 2010, American journal of physiology. Cell physiology.

[12]  R. Panettieri,et al.  Airway smooth muscle: a modulator of airway remodeling in asthma. , 2005, The Journal of allergy and clinical immunology.

[13]  A. Koleske,et al.  The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse. , 2008, Blood.

[14]  M. Rothenberg,et al.  Receptor internalization is required for eotaxin-induced responses in human eosinophils. , 2003, The Journal of allergy and clinical immunology.

[15]  J. Foidart,et al.  Mouse models of asthma: a comparison between C57BL/6 and BALB/c strains regarding bronchial responsiveness, inflammation, and cytokine production , 2009, Inflammation Research.

[16]  A. Strasser,et al.  T cell survival and function requires the c-Abl tyrosine kinase , 2008, Cell cycle.

[17]  M. Schlissel,et al.  The effects of c-Abl mutation on developing B cell differentiation and survival. , 2009, International immunology.

[18]  D. Tang,et al.  Critical Role of Vimentin Phosphorylation at Ser-56 by p21-activated Kinase in Vimentin Cytoskeleton Signaling* , 2006, Journal of Biological Chemistry.

[19]  A. Williamson,et al.  Integrin-Mediated Dendrite Branch Maintenance Requires Abelson (Abl) Family Kinases , 2005, The Journal of Neuroscience.

[20]  Jean Y. J. Wang.  Controlling Abl: auto-inhibition and co-inhibition? , 2004, Nature Cell Biology.

[21]  R. Panettieri,et al.  IL‐13 enhances agonist‐evoked calcium signals and contractile responses in airway smooth muscle , 2003, British journal of pharmacology.

[22]  D. Tang,et al.  Role of the Adapter Protein Abi1 in Actin-associated Signaling and Smooth Muscle Contraction* , 2013, The Journal of Biological Chemistry.

[23]  P. Howarth,et al.  Synthetic responses in airway smooth muscle. , 2004, The Journal of allergy and clinical immunology.

[24]  R. Schwartz,et al.  Airways in smooth muscle α-actin null mice experience a compensatory mechanism that modulates their contractile response. , 2012, Journal of applied physiology.

[25]  D. Tang,et al.  Abl regulates smooth muscle cell proliferation by modulating actin dynamics and ERK1/2 activation. , 2012, American journal of physiology. Cell physiology.

[26]  R. Penn.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[27]  M. Wills-Karp,et al.  Interleukin‐13 in asthma pathogenesis , 2004, Immunological reviews.

[28]  G. Evans,et al.  Expression and cytogenetic localization of the human SM22 gene (TAGLN). , 1998, Genomics.

[29]  P. Foster,et al.  Chemokines in asthma: cooperative interaction between chemokines and IL-13. , 2003, The Journal of allergy and clinical immunology.

[30]  D. Tang,et al.  Cdc42GAP, reactive oxygen species, and the vimentin network. , 2009, American journal of physiology. Cell physiology.

[31]  A. Halayko,et al.  The integrin-blocking peptide RGDS inhibits airway smooth muscle remodeling in a guinea pig model of allergic asthma. , 2010, American journal of respiratory and critical care medicine.

[32]  M. Laviolette,et al.  Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[33]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[34]  W. Henderson,et al.  Airway smooth muscle hyperplasia and hypertrophy correlate with glycogen synthase kinase-3(beta) phosphorylation in a mouse model of asthma. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[35]  J. Erjefält,et al.  Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels. , 2005, American journal of respiratory and critical care medicine.

[36]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[37]  R. Panettieri,et al.  Airway smooth muscle as a regulator of immune responses and bronchomotor tone. , 2006, Clinics in chest medicine.

[38]  S. Dahlén,et al.  Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. , 1992, The American review of respiratory disease.

[39]  J. Colicelli,et al.  RIN1 Is an ABL Tyrosine Kinase Activator and a Regulator of Epithelial-Cell Adhesion and Migration , 2005, Current Biology.

[40]  D. Umetsu,et al.  Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity1 , 2001, The Journal of Immunology.

[41]  R. Panettieri,et al.  Bronchial hyperresponsiveness: insights into new signaling molecules. , 2004, Current opinion in pharmacology.

[42]  D. Tang,et al.  Abl Silencing Inhibits CAS-Mediated Process and Constriction in Resistance Arteries , 2007, Circulation research.

[43]  F. Kalkbrenner,et al.  Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. , 2007, American journal of respiratory cell and molecular biology.